Market Overview - A and H shares continued to be negatively impacted by the Federal Reserve's lower-than-expected interest rate cuts, with significant declines in sectors such as non-ferrous metals and chemicals [1] - The A-share market saw the Shanghai Composite Index down 3.90%, Shenzhen Component Index down 5.13%, and ChiNext Index down 6.15% [3] - Defensive sectors like banking, media, food and beverage, and defense showed relative resilience, while sectors like power equipment, basic chemicals, and steel experienced significant declines [1][3] Industry Dynamics - The pharmaceutical industry index fell 6.88%, with sub-sectors like chemical pharmaceuticals and bioproducts declining by 7.02% and 7.46% respectively [5] - Eli Lilly became the first global healthcare company to reach a market capitalization of $1 trillion, driven by its GLP-1 weight loss drug contributing 55% of its revenue [7] - Moderna announced the termination of three mRNA projects and secured a $15 billion loan, focusing future efforts on oncology and rare diseases [7] - Innovative drug companies like BeiGene and Innovent Biologics reported significant revenue growth, with BeiGene's global revenue reaching $1 billion, up 51% year-on-year [8] Technology Sector - The technology sector faced significant adjustments, with the Hang Seng Technology Index dropping 7.18% [10] - Nvidia reported Q3 revenue of $57 billion, exceeding expectations, with data center revenue of $51.2 billion, up 66% year-on-year [17] - Google launched the Gemini 3 model, achieving breakthroughs in multi-modal understanding and reasoning capabilities, surpassing competitors [12] - Alibaba's AI application "Qianwen" quickly rose to the fourth position in the App Store rankings, aiming to become a personal AI assistant [13] Investment Strategies - Investment strategies are focusing on technological transformation and de-globalization, with an emphasis on AI and innovative pharmaceuticals [3] - The market is expected to enter a bottoming phase after two weeks of significant adjustments, with a long-term view of a structural bull market [1][3] - The focus is on identifying undervalued technology players within the overseas supply chain [2]

Core Viewpoint - The company held an online performance briefing for Q3 2025, discussing its operational and financial status, product developments, and addressing investor inquiries [1] Group 1: Company Performance and Strategy - As of the end of Q3 2025, the company's products have entered 67 countries and regions, obtaining nearly 3,300 product import licenses, indicating strong overseas market expansion [2] - The company reported a 30% year-on-year increase in chemical luminescence reagent testing volume, reflecting growing market recognition and the effectiveness of its strategy to drive reagent consumption through instrument installations [2][3] - The company achieved overseas revenue of 0.51 billion yuan in Q3 2025, a year-on-year increase of 47.34% and a quarter-on-quarter increase of 23.78% [2][4] Group 2: Product Development and Market Trends - The Metis7000 fully automated biochemical immunoassay line is designed for large hospitals, while the Metis6000 targets smaller laboratories, showcasing a complementary product matrix [3] - The company’s molecular POCT products are well-positioned to meet the rising demand for respiratory disease testing during the flu season, with significant product launches planned [2][4] - The company maintains a positive outlook on the future of its POCT product line, driven by policy support, technological advancements, and international market expansion [4] Group 3: Financial Management - The company successfully optimized its expenses, with total sales, management, and R&D expenses amounting to 368 million yuan, a decrease of 11.47% year-on-year [4] - The company is focused on enhancing resource allocation efficiency while ensuring stable business growth and necessary R&D investments [4]

Core Insights - The company held an online performance briefing on November 21, 2025, discussing its Q3 2025 operational and financial status, as well as product developments [1] Group 1: Business Performance - As of the end of Q3 2025, the company's products have entered 67 countries and regions, with nearly 3,300 product import licenses obtained, laying a solid foundation for overseas market expansion [1] - In Q3 2025, the company achieved overseas regular product revenue of 51 million yuan, a year-on-year increase of 47.34% and a quarter-on-quarter increase of 23.78% [1] - For the first three quarters of 2025, the company reported overseas self-produced regular product revenue of 124 million yuan, a year-on-year increase of 46.21%, with the POCT product line contributing 99 million yuan, up 41.61% year-on-year [1][2] Group 2: Growth Drivers - The growth in overseas business, particularly in the POCT product line, is attributed to the company's focus on international markets, optimizing the management structure of the international trade department, and enhancing product recognition [2] - The company has obtained 109 registration projects for chemiluminescence, covering key disease areas such as cardiovascular, inflammation, infectious diseases, tumor markers, thyroid function, glucose metabolism, and sex hormones [2] - The detection volume of chemiluminescence reagents increased by over 30% year-on-year, indicating a sustained improvement in market recognition and the effectiveness of the strategy to drive reagent consumption through instrument installations [2] Group 3: Future Outlook - The company plans to continue investing in R&D, focusing on instrument iteration, expanding the testing menu, and upgrading core raw material development to enhance product competitiveness and accelerate the import substitution process [3] - For the first three quarters of 2025, the company's combined sales, management, and R&D expenses totaled 36.8 million yuan, a decrease of 11.47% year-on-year, reflecting effective cost control [3] - The company aims to deepen refined management, improve resource allocation efficiency, and implement precise resource deployment in marketing while achieving digital control of expenses through an intelligent expense management system [3]

证券代码：603387 证券简称：基蛋生物 公告编号：2025-048 基蛋生物科技股份有限公司 关于 2025 年第三季度业绩网上说明会 召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 基蛋生物科技股份有限公司（以下简称"公司"）于2025年11月21日 14:00-15:00在上证所信息网络有限公司上证路演中心平台（以下简称"上证路 演中心"）采用网络互动方式召开"基蛋生物2025年第三季度业绩说明会"。关 于本次业绩说明会的召开事项，公司已于2025年10月31日在《上海证券报》及上 海证券交易所网站上披露了《基蛋生物科技股份有限公司关于召开2025年第三季 度业绩网上说明会的公告》（公告编号：2025-047）。现将有关事项公告如下： 一、本次说明会召开情况 2025年11月21日，公司董事长苏恩本先生、公司财务总监倪文先生、公司董 事会秘书刘葱女士、公司独立董事万遂人先生、公司独立董事鞠熀先先生、公司 独立董事凌华女士出席了本次业绩说明会。公司就2025年三季度经营状况、财务 状况、产品等问题与投资者 ...

Core Viewpoint - The information disclosure evaluation results for listed companies in 2024 show a significant decline in ratings for several companies, including 基蛋生物, which dropped from A to C compared to 2022 [1][2]. Group 1: Company Overview - 基蛋生物科技股份有限公司 is located in Nanjing, Jiangsu Province, and was established on March 8, 2002, with its listing date on July 17, 2017 [3]. - The company specializes in the research, production, and sales of in vitro diagnostic products, with 87.08% of its revenue coming from self-developed products and 12.92% from collaborative projects [3][4]. Group 2: Industry Classification - 基蛋生物 belongs to the pharmaceutical and biological industry, specifically in the medical device sector focusing on in vitro diagnostics [4]. - The company is associated with several concept sectors, including anti-influenza, small-cap stocks, Helicobacter pylori concept, monkeypox concept, and margin financing [4]. Group 3: Management Information - The current company secretary is Liu Cong, who has been in the position since December 18, 2020, and holds a master's degree [4][5]. - Liu Cong has previous experience as a credit manager at China Postal Savings Bank and has held various positions in corporate governance, obtaining qualifications from both Shenzhen and Shanghai stock exchanges [5].

Core Insights - The core point of the article is the disclosure of institutional and public fund holdings in基蛋生物 (603387.SH) as of the third quarter of 2025, highlighting a slight decrease in institutional ownership compared to the previous quarter [1] Institutional Holdings - As of October 30, 2025, two institutional investors disclosed holdings in基蛋生物, totaling 29.75 million shares, which represents 5.87% of the company's total share capital [1] - The institutional ownership percentage decreased by 0.07 percentage points compared to the previous quarter [1] Public Fund Holdings - In this reporting period, 39 public funds were not disclosed compared to the previous quarter, including notable funds such as 汇添富沪深300指数增强A, 医疗器械ETF, and 易方达中证万得生物科技指数(LOF)A [1]

Group 1 - The core point of the article is that 基蛋生物 (SH 603387) held its fourth board meeting on October 30, 2025, to review governance-related proposals [1] - For the year 2024, the company's revenue composition is entirely from in vitro diagnostics, accounting for 100.0% [1]

Core Insights - The company reported a revenue of 244,996,840.05 yuan for Q3 2025, representing a year-on-year decline of 6.55% [2] - The net profit attributable to shareholders of the listed company was 51,735,043.90 yuan, showing a significant year-on-year increase of 80.83% [2] Financial Performance - Revenue for Q3 2025: 244.997 million yuan, down 6.55% year-on-year [2] - Net profit for Q3 2025: 51.735 million yuan, up 80.83% year-on-year [2]

Core Viewpoint - 基蛋生物 is a leading company in the in vitro diagnostics sector in China, showcasing significant investment value due to its comprehensive industry chain advantages [1] Group 1: Business Performance - In Q3 2025, 基蛋生物 reported revenue of 758 million yuan, ranking 14th among 39 companies in the industry, with the top company generating 3.428 billion yuan [2] - The company's net profit for the same period was 150 million yuan, placing it 9th in the industry, while the leading company reported a net profit of 1.588 billion yuan [2] - The revenue from self-developed products was 446 million yuan, accounting for 87.08% of total revenue, while other revenue sources contributed 66.22 million yuan, or 12.92% [2] Group 2: Financial Ratios - As of Q3 2025, 基蛋生物's asset-liability ratio was 26.98%, down from 30.26% year-on-year, which is higher than the industry average of 18.29% [3] - The gross profit margin for the same period was 68.93%, slightly down from 69.43% year-on-year, but still above the industry average of 56.20% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 4.22% to 25,200, while the average number of shares held per shareholder increased by 4.40% to 20,100 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third largest, holding 12.8725 million shares, an increase of 7.1047 million shares from the previous period [5] Group 4: Executive Compensation - The chairman and general manager, 苏恩本, received a salary of 1.746 million yuan in 2024, which remained unchanged from 2023 [4]

关于修订及制定公司治理相关制度的公告 证券代码：603387 证券简称：基蛋生物 公告编号：2025-046 基蛋生物科技股份有限公司 | 10 | 基蛋生物：信息披露管理办法 | 修订 | 否 | | --- | --- | --- | --- | | 11 | 基蛋生物：信息披露暂缓与豁免管理制度 | 修订 | 否 | | 12 | 基蛋生物：证券投资管理制度 | 修订 | 否 | | 13 | 基蛋生物：重大信息内部报告制度 | 修订 | 否 | | 14 | 基蛋生物：自愿信息披露管理制度 | 修订 | 否 | | 15 | 基蛋生物：总经理工作细则 | 修订 | 否 | | 16 | 基蛋生物：内部审计制度 | 制定 | 否 | 三、其他说明 上述制度已经公司第四届董事会审计委员会第六次会议及第四届董事会第 八次会议审议通过，无需提交股东会审议。上述制度公司于同日在上海证券交易 所网站（www.sse.com.cn）予以披露。 特此公告。 基蛋生物科技股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...